11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $75M | -$288M | -27.8% | -358.9% | -$303M | — | $104M |
| 2024 | $10M | -$221M | -12.5% | -2385.6% | -$228M | — | $227M |
| 2023 | — | -$208M | — | — | -$157M | — | $240M |
| 2022 | — | -$149M | — | — | -$123M | — | $382M |
| 2021 | — | -$142M | — | — | -$127M | — | $310M |
| 2020 | — | -$142M | — | — | -$132M | — | — |
| 2019 | — | -$124M | — | — | -$120M | $0 | — |
| 2018 | — | -$45M | — | — | -$41M | $380000 | — |
| 2017 | — | -$20M | — | — | — | — | — |
| 2017 | — | -$20M | — | — | -$19M | $763000 | — |
| 2016 | — | -$13M | — | — | -$12M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $26M | -$72M | 6.3% | -227.0% | -$68M | — | $131M |
| Dec '25 | $24M | -$90M | -4.3% | -298.3% | -$66M | — | $104M |
| Sep '25 | $21M | -$79M | -35.1% | -337.9% | -$72M | — | $86M |
| Jun '25 | $21M | -$48M | -16.8% | -292.6% | -$80M | — | $124M |
| Mar '25 | $9M | -$70M | -99.9% | -726.3% | -$84M | — | $96M |
| Dec '24 | $29000 | -$28M | -39165.5% | -261600.0% | -$49M | — | $227M |
| Sep '24 | $0 | -$82M | — | — | -$86M | — | $657M |
| Jun '24 | $0 | -$58M | — | — | -$52M | — | $706M |
| Mar '24 | — | -$53M | — | — | -$41M | — | $759M |
| Dec '23 | — | -$77M | — | — | -$26M | — | $240M |
| Sep '23 | — | -$46M | — | — | -$42M | — | $256M |
| Jun '23 | — | -$46M | — | — | -$43M | — | $308M |
| Mar '23 | — | -$40M | — | — | -$46M | — | $343M |
| Dec '22 | — | -$27M | — | — | -$15M | — | $382M |
| Sep '22 | — | -$43M | — | — | — | — | $163M |
| Jun '22 | — | -$42M | — | — | — | — | $216M |
| Mar '22 | — | -$37M | — | — | — | — | $269M |
| Mar '21 | — | -$33M | — | — | -$39M | — | — |
| Dec '20 | — | -$43M | — | — | -$33M | — | — |
| Sep '20 | — | -$37M | — | — | -$43M | — | — |
How the market has priced AUTL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Autolus Therapeutics plc's revenue has grown 644.9% per year. These are computed facts, not advice.
As of FY2025, Autolus Therapeutics plc reported — of total debt against $104M of cash; operating income covered interest expense -7.4×.
In FY2025, gross margin was -27.8%, operating margin -358.9%, and net margin -381.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.